These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

471 related items for PubMed ID: 10917202

  • 21. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
    Tso CL, McBride WH, Sun J, Patel B, Tsui KH, Paik SH, Gitlitz B, Caliliw R, van Ophoven A, Wu L, deKernion J, Belldegrun A.
    Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
    [Abstract] [Full Text] [Related]

  • 22. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
    Lee SO, Yeon Chun J, Nadiminty N, Trump DL, Ip C, Dong Y, Gao AC.
    Prostate; 2006 Jul 01; 66(10):1070-5. PubMed ID: 16637076
    [Abstract] [Full Text] [Related]

  • 23. c-Jun enhancement of androgen receptor transactivation is associated with prostate cancer cell proliferation.
    Chen SY, Cai C, Fisher CJ, Zheng Z, Omwancha J, Hsieh CL, Shemshedini L.
    Oncogene; 2006 Nov 16; 25(54):7212-23. PubMed ID: 16732317
    [Abstract] [Full Text] [Related]

  • 24. Expression of a hyperactive androgen receptor leads to androgen-independent growth of prostate cancer cells.
    Hsieh CL, Cai C, Giwa A, Bivins A, Chen SY, Sabry D, Govardhan K, Shemshedini L.
    J Mol Endocrinol; 2008 Jul 16; 41(1):13-23. PubMed ID: 18469090
    [Abstract] [Full Text] [Related]

  • 25. Inhibition of human prostate cancer xenograft growth by 125I labeled triple-helix forming oligonucleotide directed against androgen receptor.
    Zhang Y, Ma Y, Lu HP, Gao JH, Liang CS, Liu CZ, Zou JT, Wang HQ.
    Chin Med J (Engl); 2008 Nov 20; 121(22):2284-9. PubMed ID: 19080333
    [Abstract] [Full Text] [Related]

  • 26. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
    Lazier CB, Thomas LN, Douglas RC, Vessey JP, Rittmaster RS.
    Prostate; 2004 Feb 01; 58(2):130-44. PubMed ID: 14716738
    [Abstract] [Full Text] [Related]

  • 27. Phytoestrogens from Belamcanda chinensis regulate the expression of steroid receptors and related cofactors in LNCaP prostate cancer cells.
    Thelen P, Peter T, Hünermund A, Kaulfuss S, Seidlová-Wuttke D, Wuttke W, Ringert RH, Seseke F.
    BJU Int; 2007 Jul 01; 100(1):199-203. PubMed ID: 17488304
    [Abstract] [Full Text] [Related]

  • 28. Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors.
    Kiyama S, Morrison K, Zellweger T, Akbari M, Cox M, Yu D, Miyake H, Gleave ME.
    Cancer Res; 2003 Jul 01; 63(13):3575-84. PubMed ID: 12839944
    [Abstract] [Full Text] [Related]

  • 29. Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models.
    Miyake H, Pollak M, Gleave ME.
    Cancer Res; 2000 Jun 01; 60(11):3058-64. PubMed ID: 10850457
    [Abstract] [Full Text] [Related]

  • 30. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
    Tepper CG, Vinall RL, Wee CB, Xue L, Shi XB, Burich R, Mack PC, de Vere White RW.
    Prostate; 2007 Apr 01; 67(5):521-35. PubMed ID: 17252539
    [Abstract] [Full Text] [Related]

  • 31. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
    Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, Miyamoto M.
    Cancer Res; 2003 Jan 01; 63(1):149-53. PubMed ID: 12517791
    [Abstract] [Full Text] [Related]

  • 32. Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells.
    Thelen P, Schweyer S, Hemmerlein B, Wuttke W, Seseke F, Ringert RH.
    Int J Oncol; 2004 Jan 01; 24(1):25-31. PubMed ID: 14654937
    [Abstract] [Full Text] [Related]

  • 33. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
    Xie Y, Wolff DW, Lin MF, Tu Y.
    Mol Pharmacol; 2007 Jul 01; 72(1):73-85. PubMed ID: 17430995
    [Abstract] [Full Text] [Related]

  • 34. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype.
    Hobisch A, Ramoner R, Fuchs D, Godoy-Tundidor S, Bartsch G, Klocker H, Culig Z.
    Clin Cancer Res; 2001 Sep 01; 7(9):2941-8. PubMed ID: 11555613
    [Abstract] [Full Text] [Related]

  • 35. Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines.
    Pignon JC, Koopmansch B, Nolens G, Delacroix L, Waltregny D, Winkler R.
    Cancer Res; 2009 Apr 01; 69(7):2941-9. PubMed ID: 19318561
    [Abstract] [Full Text] [Related]

  • 36. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
    Sun A, Tang J, Hong Y, Song J, Terranova PF, Thrasher JB, Svojanovsky S, Wang HG, Li B.
    Prostate; 2008 Mar 01; 68(4):453-61. PubMed ID: 18196538
    [Abstract] [Full Text] [Related]

  • 37. Exisulind and related compounds inhibit expression and function of the androgen receptor in human prostate cancer cells.
    Lim JT, Piazza GA, Pamukcu R, Thompson WJ, Weinstein IB.
    Clin Cancer Res; 2003 Oct 15; 9(13):4972-82. PubMed ID: 14581372
    [Abstract] [Full Text] [Related]

  • 38. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
    Koochekpour S, Lee TJ, Wang R, Culig Z, Delorme N, Caffey S, Marrero L, Aguirre J.
    Prostate; 2007 Feb 01; 67(2):178-89. PubMed ID: 17044040
    [Abstract] [Full Text] [Related]

  • 39. Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells.
    Yemelyanov A, Czwornog J, Gera L, Joshi S, Chatterton RT, Budunova I.
    Cancer Res; 2008 Jun 15; 68(12):4763-73. PubMed ID: 18559523
    [Abstract] [Full Text] [Related]

  • 40. Suppression of prostate tumor cell growth in vivo by WT1, the Wilms' tumor suppressor gene.
    Fraizer G, Leahy R, Priyadarshini S, Graham K, Delacerda J, Diaz M.
    Int J Oncol; 2004 Mar 15; 24(3):461-71. PubMed ID: 14767530
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.